Amarin (AMRN) received a Hold rating from Oppenheimer analyst Leland Gershell today. The company’s shares closed last Monday at $13.58.
According to TipRanks.com, Gershell is a 2-star analyst with an average return of 0.0% and a 39.8% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, BioMarin Pharmaceutical, and Corbus Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amarin with a $28.11 average price target, a 106.8% upside from current levels. In a report released yesterday, Stifel Nicolaus also maintained a Hold rating on the stock with a $8.00 price target.
See today’s analyst top recommended stocks >>
Based on Amarin’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $143 million and net profit of $7.07 million. In comparison, last year the company earned revenue of $77.33 million and had a GAAP net loss of $33.67 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.
Read More on AMRN:
